Replies to post #314578 on Bioelectronics Corp (BIEL)

[Hawk05]

KN has a new job but is still on the BOD.

As of now that would make BIEL’s management team per the site KW and JM.

[Gailm]

That was a Solid post Simpsonly:

The red flag for me initially was that not one of the 173 (178? conflicting reports) of the registered VC'S in this space has made a move for the product. ZERO.

The FDA, Testimonials, Awards all mean ZIP, NADA, NOTHING to me--------> always follow the money. And the money wants nothing to do with it. Nor do majors in tying to acquire the tech.

Then I bought 6 Actipatches. They did nothing for me or 5 other people I asked to try it, all of whom have a pain issue of one kind or another. (I also took one apart, hmmmm)

Lastly IBEX LLC, St. Johns LLC games with EXIM BANK, "family loans with no sources like a bank draft"? SEC entanglement. Yeah....NO. I think not.
So now we quietly stand vigil over the death bed of BIEL.
Trust me the OTC will be better for its winking out of existence.

[Probity]

…my sense she is not 'going to sell this company', because she simply can't. It's a publicly trading entity with multiple stockholders. She can sell her interest or that of the Whelan family. …”

Well, we know that EXIM bank holds the BIEL patents as collateral. There are different ways to skin the cat on that issue. It should not be an impediment with the right partner/merger/buyer. More below.

“ Cancel, just cancel, at least 75% of the bonus shares the Whelans claimed they're entitled to resulting from fantasy (falsified?) loans made by the Whelans to the company many years ago.

The move to this end would depend on who is doing the asking. And it has been asked by a certain someone and/or group. It was rebuffed. So, again, that circles back to: “would depend on who is doing the asking”. Can’t be the same source, unless money talks louder.

BIEL is a plug n play, turnkey company with multiple FDA clearances inclusive of musculoskeletal and Standard of Care potential (i.e., RecoveryRx). Given that…

I have written extensively for some time now about the NOPAIN Act. A potential partner or buyout prospect NOT doing their thorough due diligence about the Act NOW and seeing what it means for them, nor looking at BIEL, will be woefully behind the curve come Act time. A no-need to reinvent the wheel entry point with BIEL for prospectives.

The noise is getting louder and louder since the NOPAIN Act has passed. Many professional/advocacy/medically related organizations are now on board and pushing a start to 2024 instead of 2025…they have much influence and vast networks.

Never, ever, ever underestimate the power of government/politicians, insurance reimbursement, and the lobbying muscle of prospective’s in bringing the masses to use the product.

Well-known and established companies are always on the lookout and doing their SWOT analysis, and the upcoming NoPain Act with CMS insurance coverage is a profound development for Companies potential bottom line. Viant, and now VLMS with “medical coding” and more bubbling through. What else out there?

Everything. Has. NOW. Changed. Going. Forward.

I see no impediment for a sale with a buyer who can think and negotiate outside the box and that has an established legacy.

A monied prospective Partner/Buyer will make BIEL money woes, sales issues, loans, outstanding shares, EXIM bank patents, and whatnot, a thing of the past in a New York minute. No guarantees of a sale/partnership…

…but the game is definitely on.

All imo.